SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharma Advanced Research’s Q3 net loss widens

24 Jan 2013 Evaluate

Sun Pharma Advanced Research has reported results for third quarter ended December 31, 2012.

The company has registered a loss of Rs 24.09 crore in Q3FY13 as compared to a net loss of Rs 17.90 crore in the corresponding quarter previous year. However, the total income of the company has decreased by 6.43% at Rs 4.22 crore for quarter under review as compared to Rs 4.51 crore for the quarter ended December 31, 2011.

SPARC undertakes projects in research and technology for new chemical entities (NCE’s) or new molecules, and novel drug delivery systems. The company’s core focus is innovation and new product development for global markets.

Sun Pharma Adv. Res Share Price

147.90 -4.25 (-2.79%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Syngene Internation. 435.70
Indegene 486.80
CMS Info Systems 318.00
JITF Infralogistics 338.00
Sagility 42.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×